Table A.1.
Baseline characteristics of CKD subgroups.
| CKD G3a (N = 51) | CKD G3b (N = 24) | CKD G4 (N = 11) | |
|---|---|---|---|
| Age (years) | 73 ± 9 | 77 ± 7 | 77 ± 7 |
| Sex (M/F) | 35/16 | 16/8 | 10/1 |
| BMI (kg/m2) | 22.3 ± 3 | 22.8 ± 3 | 21.3 ± 2 |
| Angina pectoris | 18 (35%) | 10 (42%) | 3 (27%) |
| Myocardial infarction | 16 (31%) | 4 (17%) | 2 (18%) |
| Silent myocardial ischemia | 9 (18%) | 4 (17%) | 2 (18%) |
| Non-ischemic heart failure | 11 (22%) | 5 (21%) | 2 (18%) |
| Post-cardiac surgery | 16 (31%) | 8 (33%) | 6 (55%) |
| Coronary risk factor | |||
| Smoking | 29 (57%) | 12 (50%) | 9 (82%) |
| Hypertension | 29 (57%) | 16 (67%) | 9 (82%) |
| Diabetes mellitus | 16 (31%) | 12 (50%) | 5 (45%) |
| Dyslipidemia | 29 (57%) | 16 (67%) | 7 (64%) |
| Family history | 11 (22%) | 4 (17%) | 1 (9%) |
| Medications | |||
| ACE-I/ARB | 24 (47%) | 15 (63%) | 5 (45%) |
| Βeta-blocker | 35 (69%) | 13 (54%) | 10 (91%) |
| Diuretics | 34 (67%) | 20 (83%) | 9 (82%) |
| Calcium channel blocker | 11 (22%) | 9 (38%) | 5 (45%) |
| Inotropic agents | 0 (0%) | 0 (0%) | 0 (0%) |
| Blood exam | |||
| Triglyceride (casual) (mg/dl) | 133 ± 57 | 133 ± 53 | 124 ± 50 |
| LDL-Chol (mg/dl) | 93 ± 33 | 98 ± 29 | 99 ± 32 |
| HDL-Chol (mg/dl) | 54 ± 16 | 46 ± 12 | 55 ± 14 |
| Blood glucose (casual) (mg/dl) | 128 ± 38 | 128 ± 41 | 148 ± 75 |
| HbA1c (%) | 6.2 ± 0.8 | 6.2 ± 0.6 | 6.0 ± 0.8 |
| BNP (pg/ml)a | 215 ± 247 | 137 ± 119 | 455 ± 579 |
| Hb (g/dl)b | 12.8 ± 1.6 | 12.1 ± 1.4 | 10.7 ± 1.7 |
| Scr (mg/dl)c | 1.0 ± 0.2 | 1.2 ± 0.2 | 2.0 ± 0.3 |
| eGFRcr (ml/min/1.73 m2)c | 50.9 ± 8.9 | 41.5 ± 8.4 | 25.8 ± 5.3 |
| Scys (mg/l)c | 1.2 ± 0.1 | 1.6 ± 0.1 | 2.4 ± 0.3 |
| eGFRcys (ml/min/1.73 m2)c | 53.3 ± 4.0 | 38.0 ± 3.9 | 23.3 ± 3.6 |
| CRP (mg/dl)d | 0.19 ± 0.20 | 0.43 ± 0.66 | 0.67 ± 0.98 |
| Echocardiography | |||
| LVDd (mm) | 51 ± 8 | 47 ± 6 | 49 ± 8 |
| LVEF (%) | 50 ± 13 | 54 ± 11 | 49 ± 14 |
| LVEF < 40 (%) | 13 (25%) | 2 (8%) | 4 (36%) |
| 40 ≦ LVEF < 60 (%) | 25 (49%) | 13 (54%) | 3 (27%) |
| LVEF ≧ 60 (%) | 13 (25%) | 9 (38%) | 4 (36%) |
| E/e′e | 11.8 ± 4 | 12.1 ± 4 | 16.4 ± 8 |
| E/e′ < 8 | 8 (16%) | 4 (17%) | 1 (9%) |
| 8 ≦ E/e′ ≦ 14 | 31 (61%) | 13 (54%) | 4 (36%) |
| E/e′ > 14 | 12 (24%) | 7 (29%) | 6 (55%) |
| MR ≧ 3°/4 | 0 (0%) | 0 (0%) | 0 (0%) |
| CPX at the beginning of CR | |||
| Pre exercise | |||
| Heart rate (bpm) | 75 ± 16 | 77 ± 12 | 66 ± 14 |
| Systolic BP (mm Hg) | 131 ± 29 | 127 ± 18 | 145 ± 20 |
| Peak exercise | |||
| Heart rate (bpm) | 122 ± 25 | 115 ± 17 | 103 ± 24 |
| Systolic BP (mm Hg) | 171 ± 31 | 166 ± 32 | 171 ± 17 |
| AT (ml/min/kg) | 10.7 ± 2 | 10.7 ± 2 | 9.8 ± 2 |
| Peak VO2 (ml/min/kg)f | 15.7 ± 3 | 14.0 ± 3 | 13.9 ± 3 |
| Peak WR (watt) | 68.5 ± 23 | 61.6 ± 17 | 59.9 ± 17 |
| VE/VCO2 slope | 38.4 ± 7 | 38.7 ± 6 | 41.3 ± 5 |
| Peak RER | 1.17 ± 0.1 | 1.19 ± 0.1 | 1.22 ± 0.1 |
| Amount of exercise during CR at outpatient visit | |||
| Session attendance (times/3 months) | 6.2 | 7.5 | 6.5 |
a
CKD G3a vs CKD G4, CKD G3b vs CKD G4, p = 0.014.
b
CKD G3a vs CKD G4, CKD G3b vs CKD G4, p = 0.000.
c
CKD G3a vs CKD G3b vs CKD G4, p = 0.000.
d
CKD G3a vs CKD G4, p = 0.014.
e
CKD G3a vs CKD G4, CKD G3b vs CKD G4, p = 0.020.
f
CKD G3a vs CKD G3b, p = 0.036.